万泰生物：公司与泰国合作方共同推动公司九价HPV疫苗在泰国的本地化生产

Core Viewpoint - The company is collaborating with the National Vaccine Institute of Thailand (NVI) and Global Biotech Products Co., Ltd. (GBP) to localize the production of its nine-valent HPV vaccine in Thailand, ensuring the supply of raw materials and compliance with local regulations [1] Group 1: Localization Strategy - The localization strategy involves a partnership where the company supplies the raw liquid vaccine, while the Thai partner handles the packaging and release testing [1] - The project has successfully completed process validation and is progressing as planned [1] Group 2: Intellectual Property Protection - The company has not disclosed specific measures for protecting its core patented technology from leakage during the localization process [1]